Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma
Shots:
- The P-III OLE study involves assessing of Dupixent (300mg) + SOC in 2-282 adults/ adolescents with mod.-to-sev. asthma prior participated in a controlled Dupixent clinical trial- including the pivotal P-IIb DRI (24wks.) and P-III QUEST (52wks.) trials in patients with mod.-to-sev. asthma and the P-III VENTURE (24wks.) trial in patients with severe OCS-dependent asthma
- The P-III OLE study results demonstrated the safety & efficacy profile observed in previous Dupixent trials were maintained for up to 3yrs. i.e- improvement in lung function by 13-22% @96wks.- patients maintained a low rate of severe asthma attacks- AE rates (76-88%) and will be presented at 2020 ERS International Congress
- Dupixent is a mAb inhibiting the signaling of the IL-4 & IL-13 proteins and is the only biologic to demonstrate sustained improvements in lung function and asthma exacerbations across a broad patient population with type 2 inflammation
Ref: Sanofi | Image: News Medical
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com